Semaglutide Powder

Semaglutide powder, as a representative dosage unit of a new generation of GLP-1 receptor agonists, has its core value in exerting metabolic regulation through multiple physiological pathways: on the one hand, this active ingredient can intelligently sense blood glucose levels, triggering insulin release only when blood glucose rises, significantly reducing the risk of hypoglycemia; on the other hand, it prolongs satiety time by delaying gastrointestinal motility and directly acts on the brain's feeding center to weaken the desire to eat, thereby achieving the dual goals of blood glucose homeostasis and weight management.

Doses such as 10 mg and 20 mg are usually designed for specific sustained-release formulations or high-concentration formulations, aiming to prolong the duration of drug effect, reduce the frequency of administration, and improve the convenience and compliance of long-term medication for patients. It is currently widely used in clinical intervention programs for adult type 2 diabetes and obesity.

1. High-purity active ingredient: As a polypeptide active pharmaceutical ingredient, it boasts a purity exceeding 99%, high bioactivity, and strict control over impurities and endotoxins, fully meeting pharmaceutical-grade quality standards.
2. Stable and easy-to-store lyophilized form: Existing in lyophilized powder form, semaglutide powder exhibits excellent thermal and storage stability, facilitating long-term storage and cold chain transportation, effectively extending shelf life.
3. High dosage form adaptability: The powder form provides great processing flexibility, allowing for formulation into various dosage forms such as injections, oral tablets, and oral films, meeting diverse R&D and production needs.
4. Precise and controllable dosage: As an active pharmaceutical ingredient, pharmaceutical companies can precisely weigh and formulate different specifications of preparations (e.g., 5mg, 10mg, 40mg, etc.) according to formulation requirements, achieving flexible dosage customization and ensuring batch-to-batch consistency.

1. Raw Material Testing (Incoming Inspection)

Starting materials and key excipients are tested for appearance, identification (HPLC/MS), purity (HPLC ≥ 98%), and moisture content. Each batch of raw materials must provide a Supplier's Certificate of Account (COA) and undergo sampling verification. Only materials that pass the verification are released for use.

2. In-Process QC

Monitoring is implemented at key production stages: During synthesis, coupling efficiency and condensing agent residue are monitored; during purification, the purity and recovery rate of collected fractions are controlled; during freeze-drying, moisture and residual solvents are monitored, with particular attention paid to the removal effectiveness of condensing agents (DIC, DCC) and catalysts (DMAP) to ensure process control.

3.

4.Testing Equipment and Laboratory Capabilities

  Core Testing Equipment:

• HPLC (High Performance Liquid Chromatography): Used for purity determination, related substance testing, and identification.
• GC-MS/MS (Gas Chromatography-Tandem Mass Spectrometry): Used for the detection of residual condensing agents (DIC, DCC) and catalysts (DMAP). Method precision RSD < 6.0%, recovery rate 97.6%~99.2%.
• LC-Q-TOF/MS (Liquid Chromatography-Quadrupole Time-of-Flight Mass Spectrometry): Used for peptide sequence confirmation and identification of low-abundance impurities.
• 2D-LC-MS (Two-Dimensional Liquid Chromatography-Mass Spectrometry): Used for in-depth characterization of the main peak and difficult-to-separate impurities.

Laboratory Qualifications: The QC laboratory should possess CNAS/ISO 17025 accreditation, be staffed with experienced analysts, and implement a complete SOP system and data integrity management (compliant with ALCOA+ principles).

Third-Party Testing Cooperation: Independent testing and confirmation of methods, residual solvent determination, and stability studies can be commissioned to third-party testing institutions with CMA/CNAS accreditation (such as CGC).

1. Factory Area: Semaglutide powder base is located in Xi'an High-tech Zone/Xixian New Area, covering an area of ​​approximately 90,000 square meters (134 acres), with GMP workshops and supporting facilities totaling approximately 50,000-80,000 square meters.
2. GMP Workshop Level: The synthesis/purification area is Class 10,000 (ISO 7), the freeze-drying/packaging area is Class 100,000 (ISO 8), and the local laminar flow reaches Class 100 (ISO 5). It has passed the GMP compliance inspection of the Shaanxi Provincial Drug Administration.
3. Annual Production Capacity: 50-200 kg/year of active pharmaceutical ingredients (approximately 5 million-20 million vials of finished products), 20 million tablets/year of oral dosage forms, with a 30% capacity flexibility.
4. Production Lines and Automation: 2-3 synthesis lines (50L-1000L reactors), 2-3 purification lines, 2-3 freeze dryers, and 1 oral dosage form production line. The core process automation rate is over 85%.
5. Core equipment: 1000L synthesis reactor, preparative HPLC (300mm column diameter), freeze dryer (15m² shelf area), GC-MS/MS and multiple HPLC units, supporting production from gram to hundreds of kilograms.